Results 141 to 150 of about 811,174 (190)
Some of the next articles are maybe not open access.
The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors.
Clinical advances in hematology & oncology : H&ODespite significantly improving outcomes in patients with B-cell malignancies, covalent Bruton tyrosine kinase (BTK) inhibitors are limited by toxicities and the development of resistance. Some toxicities can be life-threatening, such as cardiotoxicity.
Fateeha, Furqan, Nirav N, Shah
openaire +1 more source
Recent Development of BTK-Based Dual Inhibitors in the Treatment of Cancers
European Journal of Medicinal Chemistry, 2022Chi Meng, Jianqiang Qian, Yong Ling
exaly
Pirtobrutinib Shows Evidence to Inaugurate a Third Generation of BTK Inhibitors
Lancet, The, 2021Vincent Ribrag, Jean-Marie Michot
exaly
BTK Inhibitors and Chemoimmunotherapy for CLL
Clinical Lymphoma Myeloma and Leukemia, 2020openaire +2 more sources

